Novel approaches for molecular targeted therapy against hepatocellular carcinoma

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Systemic chemotherapy with multitargeted tyrosine kinase inhibitors is standard for advanced cancers.
• Genomic analyses reveal significant intra- and intertumor heterogeneity in human hepatocellular carcinomas (HCCs).
• This heterogeneity supports the use of broad-acting therapeutic agents against multiple targets in tumor cells.

Purpose of the Study:

• To introduce the application of molecular targeted therapy using lenvatinib for advanced HCC.
• To discuss future therapeutic strategies for advanced HCC based on molecular targeted therapy.

Main Methods:

• Review of a randomized global phase III trial evaluating lenvatinib efficacy and safety.
• Analysis of comprehensive genomic data from next-generation sequencing of HCC tumors.

Main Results:

• Lenvatinib demonstrated confirmed efficacy and safety in a global phase III trial.
• Genomic insights into HCC heterogeneity provide a rationale for multitargeted therapies.
• Lenvatinib is approved as a first-line therapy, offering a new option for advanced HCC patients.

Conclusions:

• Lenvatinib represents a significant advancement in first-line treatment for advanced HCC.
• Molecular targeted therapy, exemplified by lenvatinib, is a promising approach for managing HCC.
• Future therapeutic options for advanced HCC will likely leverage genomic understanding and targeted agents.